UPDATES

$Virpax Pharmaceuticals (VRPX.US)$ On November 25, 2024, Virpax Pharmaceuticals announced it regained compliance with Nasdaq's independent director and audit committee requirements. This follows the appointment of Ms. Esha Randhawa as an independent director and audit committee member, addressing deficiencies caused by Dr. Eric Floyd's resignation on September 20, 2024.Nasdaq confirmed the company's compliance with Listing Rules 5605(b)(1) and 5605(c)(2), closing the matter. Virpax remains committed to adhering to all Nasdaq listing standards. The company had previously disclosed these developments in a Form 8-K filed on November 22, 2024.This compliance ensures Virpax's continued listing on the Nasdaq Capital Market, reinforcing its commitment to governance and regulatory standards.